drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CD19-directed CAR T cells)
drug_description
An autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy. Patient T cells are engineered to express a CAR that binds CD19; upon engagement they activate and kill CD19-expressing B-lineage cells (naive and memory B cells and CD19+ plasmablasts), inducing deep B-cell depletion and an immune reset to reduce autoantibody production and inflammation in SLE. Tested in dose escalation (~25–150×10^6 CAR+ T cells).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
relmacabtagene autoleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous patient T cells are engineered to express a CD19-specific chimeric antigen receptor; upon recognizing CD19 on B-lineage cells (naive and memory B cells and CD19+ plasmablasts), the CAR T cells become activated and kill these targets, producing deep B-cell depletion and an immune reset that reduces autoantibody production and inflammation.
drug_name
Relma-cel (relmacabtagene autoleucel)
nct_id_drug_ref
NCT05765006